Detection of p53 mutations in the plasma DNA of patients with ovarian cancer

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
J OtsukaM Kushima

Abstract

Mutation of p53 is one of the most common genetic abnormalities detected in up to 81% of cases of ovarian cancer. To evaluate the use of plasma DNA analysis as a method for somatic mutation screening, we measured the presence of p53 mutations in DNA isolated from plasma and cancer tissue from patients with ovarian cancer. We analyzed the plasma DNA for the presence of p53 mutations (exons 5-8). Of 27 cases of ovarian cancer, 12 cases (44%) had mutations of p53 in cancer tissue. In two of the 12 cases (16.7%), identical mutations were detected in DNA of their preoperative plasma. In our follow-up of the two patients with p53 mutations in their plasma, mutant DNA was undetectable in their plasma after surgery. In one case, the p53 mutation re-surfaced in their plasma 16 months after surgery, and the patient died 2 months later. We have shown that tumor-derived DNA can be detected in the plasma of some patients with ovarian cancer, particularly in those with more advanced stage.

References

Jun 6, 1991·Nature·A J LevineC A Finlay
Jun 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·J KupryjańczykD W Yandell
Sep 1, 1996·Nature Medicine·H NawrozD Sidransky
Jan 1, 1997·British Journal of Cancer·M S KopreskiC D Gocke
Dec 16, 1997·Scandinavian Journal of Clinical and Laboratory Investigation·J B de KokD W Swinkels
Nov 21, 2002·Journal of the National Cancer Institute·Hsueh-Wei ChangIe-Ming Shih

❮ Previous
Next ❯

Citations

Mar 15, 2013·The New England Journal of Medicine·Sarah-Jane DawsonNitzan Rosenfeld
Aug 16, 2006·Annals of Human Genetics·A Dansonka-MieszkowskaJ Kupryjańczyk
Jun 1, 2012·Science Translational Medicine·Tim ForshewNitzan Rosenfeld
Sep 1, 2012·Translational Oncology·Tilley Jenkins VogelElizabeth M Swisher
Aug 7, 2010·Clinica Chimica Acta; International Journal of Clinical Chemistry·Klaus JungAnja Rabien
Apr 19, 2015·Clinical Biochemistry·K M Patel, D W Y Tsui
Dec 2, 2006·Biochimica Et Biophysica Acta·M Fleischhacker, B Schmidt
Jul 11, 2006·Critical Reviews in Oncology/hematology·Mukesh Verma, Upender Manne
Jun 25, 2016·The American Journal of Pathology·Balabhadrapatruni V S K ChakravarthiSooryanarayana Varambally
Nov 26, 2015·Revista da Associação Médica Brasileira·Giselly EncinasMaria Aparecida Azevedo Koike Folgueira
Jul 29, 2017·Clinical Chemistry and Laboratory Medicine : CCLM·Lydia GiannopoulouEvi S Lianidou
Nov 15, 2017·Journal of Ovarian Research·Xianliang ChengChen Qing
Dec 19, 2018·Expert Reviews in Molecular Medicine·Ana BarbosaManuel R Teixeira
Oct 20, 2006·Critical Reviews in Clinical Laboratory Sciences·Qinghua FengNancy B Kiviat
Sep 24, 2018·Journal of Ovarian Research·Katarina KalavskaMichal Mego
Mar 11, 2018·Molecular Cancer Research : MCR·Rebecca C ArendCharles A Leath
Apr 16, 2021·Cancer Management and Research·Tao GuoLin Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.